FDA approved a supplemental New Drug Application for Caplyta (lumateperone) based on long-term data supporting reduced relapse risk in schizophrenia.
What this means
Caplyta is an antipsychotic drug that helps regulate brain chemicals involved in schizophrenia symptoms. Today FDA approved Caplyta for reducing the risk of relapse in schizophrenia, based on long-term safety and effectiveness data. This decision gives patients and doctors a new option to help maintain stability and prevent symptom return in this chronic mental health condition.
